Canaccord Genuity resumed coverage on Bioceres with a new price target
$BIOX
Agricultural Chemicals
Industrials
Canaccord Genuity resumed coverage of Bioceres with a rating of Buy and set a new price target of $17.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/19/2024 | $17.00 | Buy | Canaccord Genuity |
| 7/2/2024 | $15.00 | Buy | ROTH MKM |
| 4/6/2023 | $15.00 | Outperform | Oppenheimer |
| 9/30/2022 | $22.50 | Buy | Canaccord Genuity |
| 10/8/2021 | $21.00 | Buy | ROTH Capital |
6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)
6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)
6-K - Bioceres Crop Solutions Corp. (0001769484) (Filer)
SC 13G - Bioceres Crop Solutions Corp. (0001769484) (Subject)
SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)
SC 13D/A - Bioceres Crop Solutions Corp. (0001769484) (Subject)
Bioceres Crop Solutions (NASDAQ:BIOX), a leading global provider of sustainable crop productivity solutions, and ProFarm Group, a subsidiary of BIOX, today announced that their innovative insecticide and nematicide platform, Rinotec, has received a federal registration from the U.S. Environmental Protection Agency (EPA). Rinotec is exempt from residue tolerance requirements, reflecting the EPA's assessment of its negligible risk to human health and non-target organisms. Rinotec has already been approved for commercialization in Brazil. With both U.S. and Brazilian registrations now in place, Bioceres Crop Solutions is poised to advance its regulatory and commercial strategies in these regi
Bioceres Crop Solutions Corp. (NASDAQ:BIOX), announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its first event-specific patent covering the HB4 Wheat, IND-ØØ412-7. This approval is the first of four potential patents the company is pursuing for HB4 Wheat in the United States, securing protection for this technology and associated production system until 2042. HB4 wheat offers improved tolerance to drought and enhanced weed management options compared to conventional wheat. The technology has already been approved by the USDA for cultivation and by the FDA for food and feed use in the United States. The U.S. is the four
ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Biostax Corp (OTC:BIOX) ("Biostax" or "the Company"), a biopharmaceutical company focused on developing innovative immune restoration therapies, today announced its Board of Directors has approved and the Company intends to proceed with the voluntary delisting of its common stock from the OTC Pink marketplace. This strategic decision follows strong shareholder support, with 76.4% voting in favor of the delisting through a Joint Written Consent. The Company plans to file a Form 25 with the Securities and Exchange Commission (SEC) on March 15, 2025, initiating the delisting process. The delisting is expected to become effective ten days a
Canaccord Genuity resumed coverage of Bioceres with a rating of Buy and set a new price target of $17.00
ROTH MKM resumed coverage of Bioceres with a rating of Buy and set a new price target of $15.00
Oppenheimer initiated coverage of Bioceres with a rating of Outperform and set a new price target of $15.00
Total revenues in 2Q25 were $106.7 million 2Q25 net income was $0.6 million and Adjusted EBITDA1 was $15.4 million Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ:BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the fiscal second quarter ended December 31, 2024. Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards. All comparisons in this announcement are year-over-year (YoY), unless otherwise noted. Financial & Business Highlights Revenues in
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) today provided preliminary revenues, gross profit and adjusted EBITDA for the fiscal second quarter, ended December 31, 2024. Second quarter revenues are expected to be approximately $105 million, with gross profit of $45 million and adjusted EBITDA of $15 million. These results reflect challenging conditions in Argentina, which remains a decisive market for the financial performance of the company in the first half of the year. Farmer purchasing behavior in the country changed significantly compared to the prior year, driven by macroeconomic conditions and unfavorable weather. This, together with high channel inventories, led to lower crop prot
Bioceres Crop Solutions Corp. (NASDAQ:BIOX) ("Bioceres" or the "Company"), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, February 12, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal second quarter ended December 31, 2024. A press release detailing these results will be issued prior to the call. Bioceres Chairman & Chief Executive Officer Federico Trucco, Chief Financial Officer Enrique Lopez Lecube and Head of Investor Relations Paula Savanti will host the conference call, followed by a question-and